Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Oct;77(10):3096-3107.
doi: 10.1111/all.15374. Epub 2022 May 27.

First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy

Antonio Nieto  1 , Ángel Mazón  1 , María Nieto  1 , Ethel Ibáñez  2 , Dah-Tay Jang  1 , Susana Calaforra  3 , Pilar Alba  3 , Carmen Pérez-Francés  4 , Ruth Llusar  4 , Javier Montoro  5 , Antonio de Mateo  6 , Remedios Alamar  6 , David El-Qutob  7 , Javier Fernández  8 , Luis Moral  9 , Teresa Toral  9 , Mónica Antón  10 , Carmen Andreu  11 , Ángel Ferrer  12 , Isabel-María Flores  13 , Neus Cerdá  14 , Sandra Del Pozo  15 , Raquel Caballero  15 , José Luis Subiza  15 , Miguel Casanovas  15
Affiliations
Clinical Trial

First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy

Antonio Nieto et al. Allergy. 2022 Oct.

Abstract

Background: Polymerized allergens conjugated to non-oxidized mannan (PM-allergoids) are novel vaccines targeting dendritic cells (DCs). Previous experimental data indicate that PM-allergoids are readily taken up by DCs and induce Treg cells. This first-in-human study was aimed to evaluate safety and to find the optimal dose of house dust mite PM-allergoid (PM-HDM) administered subcutaneously (SC) or sublingually (SL).

Methods: In a randomized, double-blind, double-dummy, placebo-controlled trial, 196 subjects received placebo or PM-HDM at 500, 1000, 3000, or 5000 mannan-conjugated therapeutic units (mTU)/mL in 9-arm groups for 4 months. All subjects received 5 SC doses (0.5 ml each) every 30 days plus 0.2 ml SL daily. The primary efficacy outcome was the improvement of titrated nasal provocation tests (NPT) with D. pteronyssinus at baseline and at the end of the study. All adverse events and reactions were recorded and assessed. Secondary outcomes were the combination of symptom and medication scores (CSMS) and serological markers.

Results: No moderate or severe adverse reactions were reported. Subjects improving the NPT after treatment ranged from 45% to 62% in active SC, 44% to 61% in active SL and 16% in placebo groups. Statistical differences between placebo and active groups were all significant above 500 mTU, being the highest with 3000 mTU SL (p = 0.004) and 5000 mTU SC (p = 0.011). CSMS improvement over placebo reached 70% (p < 0.001) in active 3000 mTU SC and 40% (p = 0.015) in 5000 mTU SL groups.

Conclusions: PM-HDM immunotherapy was safe and successful in achieving primary and secondary clinical outcomes in SC and SL at either 3000 or 5000 mTU/ml.

Keywords: allergoid; clinical trial; i; mannan; mmunotherapy; polymerized.

PubMed Disclaimer

Conflict of interest statement

AN received fees of Astra‐Zeneca, Merck, Novartis. DE‐Q received fees of Chiesi, Sanofi, Stallèrgenes‐Greer, Astra‐Zeneca, Glaxo‐Smith‐kline, Roxall Medicine, and Novartis. AM, MN, EI, DJ, SC, C P‐F, JM, A de M, RA, JF, LM, MA, CA, and AF declare no conflict of interest. RC and SdP are employees of Inmunotek SL. JLS and MC are shareholders of Inmunotek SL.

Figures

FIGURE 1
FIGURE 1
Distribution of groups and study schedule
FIGURE 2
FIGURE 2
Consort diagram of the study population. NPT*: number of subjects with data of NPT al baseline (VO) and at the end (V6)
See this image and copyright information in PMC

References

    1. Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of allergy, asthma and immunology. Ann Allergy Asthma Immunol. 1998;81(5):401‐405. doi:10.1016/s1081-1206(10)63136-5 - DOI - PubMed
    1. Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clinical and Translational Allergy. 2017;7(1):2‐16. doi:10.1186/s13601-017-0159-6 - DOI - PMC - PubMed
    1. Cuesta‐Herranz J, Laguna JJ, Mielgo R, et al. Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA). Eur Ann Allergy Clin Immunol. 2019;51(05):222. doi:10.23822/eurannaci.1764-1489.104 - DOI - PubMed
    1. Frati F, Dell'Albani I, Incorvaia C. Long‐term efficacy of allergen immunotherapy: what do we expect? Immunotherapy. 2013;5(2):131‐133. doi:10.2217/imt.12.154 - DOI - PubMed
    1. Penagos M, Eifan AO, Durham SR, Scadding GW. Duration of allergen immunotherapy for long‐term efficacy in allergic Rhinoconjunctivitis. Curr Treat Options Allergy. 2018;5(3):275‐290. doi:10.1007/s40521-018-0176-2 - DOI - PMC - PubMed

Publication types